Product Description
Mechanisms of Action: CYP3A4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Alaunos Therapeutics
Company Location: BOSTON MA 02129
Company CEO: Kevin S. Boyle
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Glioblastoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ATI001-204 | P2 |
Completed |
Glioblastoma |
2021-08-05 |
57% |
| ATI001-204 | P2 |
Completed |
Glioblastoma |
2021-08-05 |
57% |